MedTrace Logo

CBP-0276 to Reduce Opioid Use in Adults Undergoing Major Orthopedic Surgery

NCT07687966 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-07-07

No results posted yet for this study

Summary

Randomized, double-blind, clinical study to evaluate the safety and efficacy of CBP-0276 at doses of 600 mg/day in reducing opioid use in pain management in adult patients undergoing major orthopedic surgery. Subjects will be allocated in 2 groups. One group will receive oxycodone (standard of care) + CBP-0276 at a dose of 600 mg, orally once daily for 28 days. A second group will receive oxycodone (standard of care) + placebo for CBP-0276, orally once daily for 28 days

Conditions

  • Hip or Knee Replacement

Interventions

DRUG

CBP-0276

Oxycodone CBP-0276 orally 600mg QD, orally once a day for 30 days

DRUG

Placebo for CBP-0276

Oxycodone (standard of care) + placebo for CBP-0276, orally once daily for 30 days

Sponsors & Collaborators

  • Clarent Biopharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Jorge González Thompson, MD · Innovacion y Desarrollo de Estrategias en Salud SA de CV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-08
Primary Completion
2026-06-30
Completion
2026-09-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07687966 on ClinicalTrials.gov